prednimustine
Trade name: Mostarina
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1995 (NCT00002905)
Timeline
1990s
- Jan 1, 1995
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1- Mol. weight
- 646.65 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103751 ↗
Also known as
- prednimustine
- prednimustine
- prednimustine
- prednimustine
- prednimustine
- prednimustine
- prednisolone chlorambucil ester
- sterecyt
- stereocyt
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002905 | Phase 2 | Jun 1, 1995 | Centro di Riferimento Oncologico - Aviano |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centro di Riferimento Oncologico - Aviano | Academic/Hospital | 1 | 1 | 1 | 1995 |
1 organizations
Page 1 / 1